United Kingdom Musculoskeletal
Disorders Treatment Drugs Market is primarily going to be driven by the growing
geriatric population in constituent countries of the United Kingdom, such as
England, Wales, Southern Ireland, and Scotland, during the forecast period. Musculoskeletal
disorders are a group of diverse conditions that affect muscles, bones,
tendons, ligaments, and other supportive structures of the body. These
disorders comprise long-term conditions such as back problems, gout, juvenile
arthritis, rheumatoid arthritis, osteoarthritis, and osteoporosis. Some of the
leading factors that increase the chances of musculoskeletal disorders in a
person include improper posture, traumatic injuries, genetic disorders,
systemic diseases such as arthritis, lupus, or fibromyalgia, repetitive motions
of the body, and others. In the United Kingdom, over 20 million people are
diagnosed with various musculoskeletal conditions such as back pain or
arthritis every year. The National Health Service (NHS) of the United Kingdom
is actively participating in controlling the prevalence of musculoskeletal
disorders by providing quick access to specialists such as rheumatologists and
orthopedic surgeons, occupational therapy, pain management clinics, and
physiotherapy. Moreover, the growing demand for medications among people
instead of undergoing surgeries is also a significant aspect expected to
register impressive growth in the musculoskeletal disorders treatment drugs
market in upcoming years. The incorporation of novel techniques in hospitals
for the treatment of musculoskeletal diseases and improving the healthcare
system of the United Kingdom are also other factors expected to propel the
growth of the United Kingdom Musculoskeletal Disorders Treatment Drugs Market
in the forecast period.
Growing Prevalence of
Musculoskeletal Disorders
Musculoskeletal disorders
encompass a wide range of conditions that affect several joints of the body,
leading to pain, stiffness, and limited mobility. Several prominent reasons are
increasing the instances of musculoskeletal disorders in the United Kingdom.
Occupational hazards caused by industries that demand physical tasks, sedentary
lifestyles of people including physical inactivity, genetic predisposition, and
growing demographics are contributing to the emergence of musculoskeletal
conditions in the country. According to the data revealed by the United Kingdom
Government, it has been observed that in 2018, women reported a significantly
higher prevalence of musculoskeletal conditions than men (19% compared with
14.9%). The prevalence in the English, Scottish, Welsh, and Northern Irish
ethnic group was estimated to be around 19%. Moreover, rates of musculoskeletal
disorders also varied by working status, with higher instances of disorders
recorded in the 'retired' working status group (33.8%) and the lowest in those
who were in full-time education (2.6%). Based on the scenario of 2021, certain
joint disorders that dominated the health of people in the United Kingdom
include osteoporosis, osteoarthritis, back pain, rheumatoid arthritis, and
fibromyalgia. According to a survey conducted by BMC Health Services Research
in 2022, by specialty, the greatest proportion of professionals diagnosing
fibromyalgia were rheumatologists (100.0%), followed by physicians in pain
medicine (83.0%) and general practitioners (69.7%). The results of the
diagnosis depicted that out of 1697 respondents, 717 (42.3%) people were
suffering from fibromyalgia, which accounted for the majority of adults (86.6%)
followed by adolescents (12.7%). The growing prevalence rate of musculoskeletal
disorders is increasing people's concern for their health. Therefore, the
growing demand for drugs and treatments for the management of musculoskeletal
discomfort is expected to register lucrative growth in the United Kingdom
Musculoskeletal Disorders Treatment Drugs Market in the forecast period.
Increase in Geriatric Population
The growing rate of the geriatric
population in developing regions of the United Kingdom is one of the
predominant factors supporting market growth. This demographic shift is
primarily due to factors such as improved healthcare, advancements in medical
technology, and a generally higher standard of living. Currently, there are
over 15.5 million people aged above 60 years, making up 23% of the United
Kingdom's population. About 4 million older people (40% of people over the age
of 65) have long-term disabling illnesses or disabilities. Certain
musculoskeletal disorders that are found to be more prevalent among elderly
people include osteoarthritis, rheumatoid arthritis, and osteoporosis. Two
varieties of osteoarthritis that are common among the elderly population in
England are knee osteoarthritis and hip osteoarthritis. According to the report
provided by Public Health England, it has been observed that in Kensington and
Chelsea, around 8,311 people aged above 45 years are suffering from knee
osteoarthritis, which accounts for a male prevalence of 13.1%, followed by a
female prevalence of 15.9%. Moreover, in England, a total of 5,456 people aged
above 45 years were diagnosed with hip osteoarthritis, including 1,858 males
(6.9%) and 3,598 females (11.9%). Some preventive and therapeutic approaches
for geriatric individuals suffering from musculoskeletal disorders include the
consumption of a healthy diet, medication management, regular check-ups, and
others. Moreover, the growing demand for drugs depending on the specific
condition and individual patient factors is also expected to register
impressive growth in the United Kingdom Musculoskeletal Disorders Treatment
Drugs Market in the forecast period.
Download Free Sample Report
Growing Demand for Medications
The rise in the incidences of
musculoskeletal disorders has led to a growing demand for effective treatment
options in the United Kingdom. The growing preference of people towards
medication over surgical procedures due to certain reasons such as cost considerations,
risks and complications, and efficacy of medicines in managing medical
conditions is propelling the demand for drugs in the market. The choice of drug
can vary depending on the age and medical conditions of individual patients.
However, some of the common drugs generally consumed by people to prevent their
musculoskeletal problems include Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
such as ibuprofen, naproxen, and diclofenac, Acetaminophen, Opioids,
Bisphosphonates, Disease-Modifying Antirheumatic Drugs (DMARDs), and
Corticosteroids. Moreover, advances in drug therapies and improvements in the
properties of medicines are also influencing the growth of the United Kingdom
Musculoskeletal Disorders Treatment Drugs Market. Biologic drugs, such as anti-TNF
(tumor necrosis factor) agents, have revolutionized the treatment of conditions
like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in
recent years. Drugs like adalimumab (Humira), etanercept (Enbrel), and
infliximab (Remicade) are widely used in the UK to manage these disorders.
Moreover, for the treatment of osteoporosis, common medicines prescribed for
the management of this condition of weak and brittle bones include alendronate
(Fosamax) and risedronate (Actonel).
Development in Healthcare
Infrastructure
The growing demand for
medications to treat musculoskeletal disorders has been greatly influenced by
the number of hospitals established in the United Kingdom every year. According
to the analysis conducted by Statista in 2022, around 1,910 new hospitals were
built in the UK in 2018, followed by 1,978 hospitals in 2019, 1,921 hospitals
in 2020, and so on. Moreover, the availability of more than 5,000
orthopedic surgeons in the region, who are capable of treating severe musculoskeletal
disorders in patients using skilled techniques, is also expected to contribute
to the lucrative growth of the United Kingdom's Musculoskeletal Disorders
Treatment Drugs Market in the forecast period.
Recent Developments
- In
September 2021, Novartis announced that the U.S. Food and Drug Administration
(FDA) has granted fast-track designation to LNA043 for the treatment of
osteoarthritis of the knee.
- In
September 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson
announced that the U.S. Food and Drug Administration (FDA) has approved SIMPONI
ARIA (golimumab) for patients 2 years of age and older for the treatment of
active polyarticular juvenile idiopathic arthritis (pJIA).
United Kingdom Musculoskeletal Disorders
Treatment Drugs Market is segmented based on Drug Type, Route of
Administration, Distribution Channel, Drug Classification, Company, and Region.
In terms of drug type, the market is categorized into Analgesics, DMARDS,
Corticosteroids, and Others. Based on, route of administration, the market is
divided into Oral and Parenteral. On the basis of distribution channel, the market
is segmented into Hospital Pharmacies, Online Providers, Drug Stores, and
Retail Pharmacies. Based on drug classification, UK musculoskeletal disorders
treatment drugs market is fragmented into Branded Drugs and Generic Drugs.
Market Players
GlaxoSmithKline plc., AstraZeneca PLC., Novartis
Pharmaceuticals UK Ltd., Bayer plc., Johnson & Johnson Pvt. Ltd., Reckitt
Benckiser Group PLC., F. Hoffmann-La Roche Ltd., Marksans Pharma Ltd.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, and CAGR for 2018-2022
and 2023-2028
|
|
Report coverage
|
Revenue forecast, company
share, competitive landscape, growth factors, and trends
|
|
Segments covered
|
Drug Type
Route of Administration
Distribution Channel
Drug Classification
|
|
Regional scope
|
London, East Anglia,
Southwest, Southeast, Scotland, East Midlands, Yorkshire & Humberside
|
|
Key companies profiled
|
GlaxoSmithKline plc., AstraZeneca PLC.,
Novartis Pharmaceuticals UK Ltd., Bayer plc., Johnson & Johnson Pvt.
Ltd., Reckitt Benckiser Group PLC., F. Hoffmann-La Roche Ltd., Marksans
Pharma Ltd.
|
|
Customization scope
|
10% free report
customization with purchase. Addition or alteration to country, regional
& segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to
meet your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF
and Excel through Email (We can also provide the editable version of the
report in PPT/Word format on special request)
|
Report
Scope:
In
this report, United Kingdom Musculoskeletal Disorders Treatment Drugs Market has
been segmented into following categories, in addition to the industry trends
which have also been detailed below:
·
United
Kingdom Musculoskeletal Disorders Treatment Drugs Market, By Drug Type:
o
Analgesics
o
DMARDS
o
Corticosteroids
o
Others
·
United
Kingdom Musculoskeletal Disorders Treatment Drugs Market, By Route of
Administration:
o
Oral
o
Parenteral
·
United
Kingdom Musculoskeletal Disorders Treatment Drugs Market,
By Distribution Channel:
o
Hospital
Pharmacies
o
Online
Providers
o
Drug
Stores
o
Retail
Pharmacies
·
United
Kingdom Musculoskeletal Disorders Treatment Drugs Market, By Drug
Classification:
o
Branded
Drugs
o
Generic
Drugs
·
United
Kingdom Musculoskeletal Disorders Treatment Drugs Market, By Region:
o
Southeast
o
Midwest
o
South
o
West
Competitive
Landscape
Company
Profiles: Detailed analysis of the major companies present in United
Kingdom Musculoskeletal Disorders Treatment Drugs Market.
Available
Customizations:
With
the given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
o
Detailed
analysis and profiling of additional market players (up to five).
United
Kingdom Musculoskeletal Disorders Treatment Drugs Market is an upcoming report
to be released soon. If you wish an early delivery of this report or want to
confirm the date of release, please contact us at [email protected]